Authors:I. Abdel-Ghany, A. El-Bayoumy, N. Elmouhty, and H. Shafik
Human AFP was used as an antigen for the development of monoclonal antibodies by the hybridoma technique. Balb/c mice were
immunized with highly purified AFP. The preparation of I125-AFP was carried out by lactoperoxidase oxidation method, preparation of AFP standards was carried out from cord sera. The
antibody titer of the serum was tested by RIA-AFP system. The spleen of the immunized Balb/c was fused with Sp20 mouse myeloma cells. The cells from the positive hybridomas were cloned twice using limiting dilution method. Eleven stable
clones were thus established for secreting monoclonal antibodies to AFP. Cells in this growth phase were chosen for freezing.
pharmacodynamic data [ 13 ].
Batch vs. Flow-Based Production of Biotherapeutics
Therapeutic antibodies are mainly produced in mammalian host cell lines such as Chinese hamster ovary (CHO) and murine myeloma cells (NS0). The
Authors:C. Nath Nath, L. Zeng, A. Eslick, J. Trotman, and J. Earl Earl
A simple isocratic HPLC-UV assay for measurement of total and free melphalan concentrations in human plasma is described. Samples were prepared by methanol precipitation (total melphalan assay) and ultrafiltration (free melphalan assay). On a 25 cm × 4.6 mm C18 column with 0.016 m mixed soldium phosphate citrate buffer (pH 3.75)-acetonitrile 87:13 as mobile phase, at a flow rate of 1 mL min−1, the retention time of melphalan was 11.5 min. Detection was at 254 nm. For total melphalan assay response was a linear function of concentration up to 40 μg mL−1, with excellent interday precision (<6% for 0.5–40 μg mL−1 melphalan), accuracy (<2% deviation from the true concentration), and recovery (91–110%). For free melphalan assay response was a linear function of concentration up to 2.5 μg mL−1, with good precision (<11% for 0.7–2.5 μg mL−1 melphalan) and recovery (89–93%). Detection limits were 0.1 μg mL−1 and 0.05 μg mL−1 for total and free melphalan assays, respectively. The assays were clinically applied in a study of myeloma patients.
Authors:Berta Holló, Milena Krstić, Sofija P. Sovilj, György Pokol, and Katalin Mészáros Szécsényi
compounds to about 350 °C is endothermic. Whether this difference could be related to the considerably higher cytotoxicity of this compound against MDA-MB-432 (breast cancer), SW-480 (colon adenocarcinoma), and IM9 (myeloma multiple) cell lines [ 12